10-K: Fortive Reports 2025 Results, Navigates Spin-Off & Leadership Shifts

Fortive Corporation reported a 1.9% increase in total revenue for 2025, alongside a strategic spin-off of Ralliant and significant leadership transitions.

Summary

• Total revenue from continuing operations increased by 1.9% to $4,159.1 million in 2025, with core revenue growth of 1.7%.
• Net earnings from continuing operations rose to $532.7 million in 2025 from $482.5 million in 2024.
• Operating profit margin for continuing operations slightly decreased to 17.3% in 2025 from 17.6% in 2024.
• The Intelligent Operating Solutions (IOS) segment saw sales grow by 2.3% to $2,856.3 million and operating profit margin increase by 50 basis points to 25.8%.
• The Advanced Healthcare Solutions (AHS) segment's sales increased by 1.2% to $1,302.8 million, but its operating profit margin decreased by 20 basis points to 10.6% due to modest volume decline.
• The company completed the separation of its Precision Technologies segment into Ralliant Corporation on June 28, 2025, which is now reported as a discontinued operation.
• Fortive repurchased 30.4 million shares of common stock for approximately $1.61 billion during 2025.
• Cash and equivalents decreased to $375.5 million at year-end 2025 from $813.3 million in 2024, primarily due to share repurchases and debt repayments.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a stable but decelerating performance. While strategic actions like the Ralliant spin-off and debt reduction are positive, the slowdown in revenue growth and slight margin compression, particularly in the AHS segment, warrant a neutral-to-slightly-positive outlook.

Positives

• Net earnings from continuing operations increased by $50.2 million to $532.7 million in 2025.
• Operating cash flow from continuing operations remained strong at $1,035.7 million in 2025, a slight increase from $1,028.5 million in 2024.
• The Intelligent Operating Solutions (IOS) segment achieved 2.1% core revenue growth and expanded its operating profit margin by 50 basis points to 25.8% in 2025.
• The company successfully completed the tax-free spin-off of Ralliant Corporation, streamlining its portfolio.
• Significant debt reduction occurred in 2025, with total long-term debt principal decreasing from $3,718.8 million to $3,213.5 million.
• Interest expense, net, decreased to $120.5 million in 2025 from $152.8 million in 2024, driven by lower outstanding debt and interest rates on variable-rate debt.
• The company repurchased 30.4 million shares of its common stock for approximately $1.61 billion in 2025, demonstrating commitment to shareholder returns.
• Management concluded that internal control over financial reporting was effective as of December 31, 2025.

Negatives

• Total revenue growth slowed to 1.9% in 2025 from 4.3% in 2024.
• Operating profit margin for continuing operations slightly decreased by 30 basis points to 17.3% in 2025.
• The Advanced Healthcare Solutions (AHS) segment experienced a modest volume decline due to reduced demand for sterilization equipment and biomedical test products, impacted by recent changes in healthcare policy.
• Cash and equivalents decreased significantly from $813.3 million in 2024 to $375.5 million in 2025.
• The company incurred $112 million in Separation-related costs during 2025 related to the Ralliant spin-off.
• Stock-based compensation costs increased, including incremental costs related to the Separation, contributing to an unfavorable impact on operating profit margins.
• Discrete restructuring charges negatively impacted operating profit margins in both 2025 and 2024.

Risks

• Global economic conditions, including slower growth, reduced demand, inflation, interest rate changes, and geopolitical events, may adversely affect business and financial results.
• Inability to adjust manufacturing capacity, supply chain management, or purchases to reflect changes in market conditions, international trade policies, customer demand, and supply chain disruptions could harm profitability.
• Reliance on sole or limited sources of supply for certain materials, components, and services could cause production interruptions, delays, and inefficiencies.
• Fluctuations in the cost and availability of commodities or components used in operations could adversely affect financial results if cost increases cannot be passed on.
• Growth could suffer if served markets decline, do not grow as anticipated, or experience cyclicality, leading to decreased demand.
• Intense competition may lead to decreased demand, reduced market share, or the need to reduce prices for products and services.
• Growth depends on the timely development, commercialization, and customer acceptance of new and enhanced products and services based on technological innovation; failure to do so could lead to obsolescence.
• The ability to successfully manage leadership transitions and attract, develop, and retain senior leaders and other key employees is critical to success.
• Disruptions in, or breaches in security of, information technology systems, exfiltration of confidential data, and other cyberattacks could adversely affect business, reputation, and financial results.
• Defects and unanticipated use or inadequate disclosure with respect to products (including software) or services could adversely affect business, reputation, and financial results, potentially leading to recalls or liability claims.
• Adverse changes in relationships with, or the financial condition, performance, purchasing patterns, or inventory levels of, key distributors and other channel partners could adversely affect financial results.
• Work stoppages, works council campaigns, and other labor disputes could adversely impact productivity and results of operations.
• Loss to facilities, supply chains, distribution systems, or information technology systems due to catastrophe or other events could seriously harm operations.
• Inadequate protection of intellectual property, or infringement by third parties, may result in competitive injury or significant enforcement resources.
• Third parties may claim infringement or misappropriation of their intellectual property rights, leading to significant litigation expenses, losses, or licensing expenses, or preventing product sales.
• Restructuring activities could have long-term adverse effects on the business, including reducing available talent and slowing improvements.
• A variety of litigation and other legal and regulatory proceedings could adversely affect financial results and reputation.
• Climate change, or legal/regulatory measures to address it, may negatively affect the company through physical risks or increased compliance costs.
• Challenges with properly managing the use of artificial intelligence (AI) in business and products could result in reputational harm, competitive harm, and legal liability.
• International economic, political, legal, compliance, and business factors (e.g., regional conflicts, trade protection, currency volatility) could negatively affect financial results.
• Trade relations between the United States and other countries, including tariffs and sanctions, could have a material adverse effect on business and financial results.
• Foreign currency exchange rates, including volatility, may adversely affect financial results through transactional and translational effects.
• Failure to execute disciplined capital allocation, including identifying and acquiring businesses at appropriate prices, could hinder strategy.
• Acquisitions, investments, joint ventures, and other strategic relationships involve financial, accounting, managerial, operational, legal, and compliance risks.
• Indemnification provisions of acquisition agreements may not fully protect against unexpected liabilities.
• Divestitures or other dispositions could negatively impact the business, and contingent liabilities from sold businesses could adversely affect financial results.
• Potential indemnification liabilities to Ralliant and Vontier pursuant to separation agreements could materially and adversely affect businesses, financial condition, results of operations, and cash flows.
• Changes in industry standards and governmental regulations may reduce demand for products/services or increase expenses, particularly in healthcare and environmental sectors.
• Improper conduct by employees, agents, or business partners could impair reputation, ability to do business, and financial results due to violations of anti-bribery, fraud, or other laws.
• Operations, products, and services expose the company to environmental, health, and safety liabilities, costs, and violations.
• Failure to comply with extensive regulations, including healthcare regulations (e.g., FDCA, Anti-Kickback Statute, HIPAA, False Claims Act), anti-bribery, data privacy (e.g., GDPR, CCPA), environmental, export/import, and competition laws, could adversely affect financial results and reputation.
• Changes in effective tax rates or exposure to additional tax liabilities/assessments could affect profitability, and tax audits could result in additional payments.
• Significant liability could be incurred if the Separation Transactions (Danaher, Vontier, Ralliant) are determined to be taxable.
• Changes in U.S. GAAP could adversely affect reported financial results and require significant changes to internal accounting systems.
• The company may be required to recognize impairment charges for goodwill and other intangible assets, which totaled approximately $9.5 billion as of December 31, 2025.

Future Outlook

The company anticipates that currency exchange rates will positively impact 2026 estimated sales by approximately 0.8% relative to 2025 performance, assuming year-end 2025 exchange rates prevail. Management continues to monitor global economic conditions, trade policies, and regulatory changes, deploying the Fortive Business System (FBS) to manage challenges and optimize operations. The company expects to have sufficient liquidity to satisfy cash needs for the foreseeable future, including funding existing businesses, strategic acquisitions, debt payments, and dividends.

Management Comments

• Our teams across our operating companies are united by our culture of continuous improvement characterized by the high expectations, inclusion, humility, and transparency embodied in the Fortive Business System (FBS).
• FBS enables us to operate our businesses with a focus on relentless execution, powered by our mindset and a set of tools and best practices consistently applied across our portfolio.
• We are continually evolving FBS to accelerate and sustain progress in every aspect of our business and deliver on our Fortive Accelerated strategy of faster profitable growth, disciplined capital allocation and building and maintaining investor trust.
• Our people are the foundation of this Fortive Accelerated growth strategy. Creating an outstanding employee experience, where each team member feels empowered, supported, and proud is a critical driver of our sustainable success.
• We are making significant investments, organically and through acquisitions, to address technological change in the markets we serve and to improve our manufacturing, research and development, and customer-facing resources in order to be responsive to our customers throughout the world.

Industry Context

StockSavvy.ai notes that Fortive's performance in 2025 reflects a mixed industry environment. While the Intelligent Operating Solutions segment demonstrated resilience and growth, the Advanced Healthcare Solutions segment faced headwinds from changes in healthcare policy, impacting demand for certain products. The successful spin-off of Ralliant Corporation aligns with a broader industry trend of companies streamlining portfolios to focus on core competencies and unlock shareholder value. The company's emphasis on the Fortive Business System (FBS) and AI integration positions it to adapt to technological shifts and competitive pressures, particularly from low-cost manufacturers and market consolidation.

Comparison to Industry Standards

• Fortive's core revenue growth of 1.7% in 2025, while positive, is a deceleration from 4.3% in 2024, suggesting a more challenging growth environment compared to prior periods. This trend should be benchmarked against diversified industrial and healthcare technology peers to assess relative performance.
• The operating profit margin of 17.3% in 2025, a slight decrease from 17.6% in 2024, indicates some pressure on profitability, potentially due to higher employee compensation, restructuring costs, and volume declines in certain segments. Comparison to industry leaders like Danaher (its former parent) or other industrial tech conglomerates would provide context on margin efficiency.
• The Intelligent Operating Solutions segment's 2.1% core revenue growth and 25.8% operating profit margin demonstrate strong performance, potentially outperforming some competitors in professional instrumentation and software solutions, especially given the mitigation of tariff impacts.
• The Advanced Healthcare Solutions segment's modest volume decline due to healthcare policy changes highlights vulnerability to regulatory shifts, a common challenge for medical device and healthcare solution providers. This performance should be compared to specialized healthcare technology companies to understand the severity of the impact.
• The significant share repurchase program ($1.61 billion in 2025) and debt reduction post-Ralliant spin-off indicate robust capital management, potentially exceeding the capital return strategies of some peers who might be more focused on M&A or organic reinvestment.

Management Changes

Corporate Governance

Legal Proceedings

• The company is subject to a variety of litigation and other legal and regulatory proceedings incidental to its business, including claims for damages from product use, intellectual property matters, employment matters, commercial disputes, and personal injury, as well as regulatory investigations.
• Management believes that these proceedings and claims will not have a material adverse effect on the company's financial position, results of operations, or cash flows.

Related Party Transactions

• A charitable contribution of $20.0 million was made to the Fortive Foundation, a related party, in the first quarter of 2024. The Foundation is considered a related party due to certain Fortive executives serving as members of its board of directors.

Stakeholder Impact

• **Shareholders**: Benefited from the Ralliant spin-off, which distributed Ralliant common stock pro rata, and significant share repurchases totaling $1.61 billion in 2025. Quarterly dividends of $0.06 per share are maintained.
• **Employees**: Experienced leadership transitions in key executive roles (CEO, CFO, CPO) and workforce reductions as part of restructuring activities. The company emphasizes an inclusive growth culture, career development, and competitive total rewards programs.
• **Customers**: The Intelligent Operating Solutions segment continues to provide advanced instrumentation, software, and services. The Advanced Healthcare Solutions segment faced reduced demand for certain products due to healthcare policy changes, potentially impacting customer adoption.
• **Suppliers**: The company's supply chain management is critical, with reliance on sole or limited sources for some components, exposing suppliers to potential disruption risks. The company works collaboratively with suppliers to manage material and shipping costs.
• **Creditors**: Debt obligations were reduced in 2025 through repayments funded by the Ralliant dividend, improving the company's leverage profile. The company maintains a $2.0 billion revolving credit facility for liquidity.

Next Steps

• Continue to monitor global economic conditions, trade policies, and regulatory changes.
• Deploy the Fortive Business System (FBS) to manage challenges and optimize production and logistics.
• Utilize pricing, cost, and productivity actions and other countermeasures to offset market dynamics.
• Make investments, organically and through acquisitions, to address technological change and improve manufacturing, R&D, and customer-facing resources.
• Refinance 248 million of the outstanding principal on the 2026 Notes and accrued interest thereon during February 2026, primarily using commercial paper proceeds.
• The 2026 Proxy Statement for the annual meeting of stockholders will be filed within 120 days after the fiscal year-end.

Key Dates

Recommendation

Fortive's 2025 performance shows a company in transition, successfully executing a major spin-off (Ralliant) and reducing debt, which are positive structural changes. However, the deceleration in core revenue growth and a slight dip in overall operating margins, particularly the volume decline in the Advanced Healthcare Solutions segment due to policy changes, suggest some near-term headwinds. The significant share repurchases are a strong signal of management's confidence and commitment to shareholder returns. Given the mixed signals of strategic execution and operational challenges, a 'hold' recommendation is appropriate for a seasoned investor. It allows for observation of how the new leadership team navigates the slowing growth and integrates AI capabilities, while acknowledging the solid financial position and capital allocation strategy.

Keywords

Fortive, 10-K, Annual Report, Financial Results, Intelligent Operating Solutions, Advanced Healthcare Solutions, Ralliant Spin-off, SEC Filing, Corporate Governance, Share Repurchase, Debt Management, Cybersecurity, Risk Factors, Leadership Transition, Financial Performance, Industrial Technology, Healthcare Solutions, FBS, Capital Allocation